For example, with BRCA1/2 loss-of-function mutations that impair BRCA-related protein functions, determining tumor sensitivity to poly [ADP-ribose] polymerase (PARP) inhibitors is critical42. This evidence concerns the gene BRCA1 and neoplasm.